With a market capitalization (market cap) of $52.39B — a measure of how much the company is worth — Edwards Lifesciences Corporation is the 315th most valuable company in Healthcare as of August 19, 2026. Shares trade at $90.98, up +0.19% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Visit websiteAs of August 19, 2026, Edwards Lifesciences Corporation (EW) is worth $52.39B — this is its market capitalization, the total value of all its outstanding shares.
Edwards Lifesciences Corporation’s market cap is $52.39B, which ranks it #315 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Edwards Lifesciences Corporation (EW) shares trade at $90.98, up 0.19% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Edwards Lifesciences Corporation trades at a price-to-earnings (P/E) ratio of 49.4, based on its latest share price and annual earnings per share.